Back to results
US 5,686,436 AGranted
Multi-faceted method to repress reproduction of latent viruses in humans and animals
AssigneeHIV Diagnostics, Inc.
InventorKnox Van Dyke
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for repressing reproduction of latent viruses, such as HIV, in animals by the generally concurrent administration of (1) antioxidants including a glutathione agent; and (2) an NFKB induction inhibitor. Also disclosed are pharmaceutical compositions and kits for use in repressing reproduction of latent viruses such as HIV.
Claims30
A method for suppressing the reproduction of human immunodeficiency virus in a human, comprising administering to such human:
- (i) at least one NFKB induction inhibitor in an amount effective to inhibit nuclear factor kappa B;
- said at least one NFKB induction inhibitor being selected from the group consisting of anti-inflammatory steroids and nonglucocorticoid lazaroids;
- (ii) at least one fat-soluble antioxidant at doses higher than the recommended daily minimum requirement;
- (iii) at least one water-soluble antioxidant at doses higher than the recommended daily minimum requirement;
- and
- (iv) at least one agent in an amount effective to cause blood glutathione levels to increase, selected from the group consisting of glutathione, N-acetyl cysteine, 2-oxo-4 thiazolidine carboxylic acid, ebselen oltipraz, L-cysteine, N-acetyl cysteine ethyl ester, N-acetyl cysteine methyl ester, cystamine, cysteamine, penicillamine, 2,3 dimercapto-1-propanol, L-2-oxothiazolidone-4-carboxylate, dimethyl maleate, glutathione ethyl ester, glutathione methyl ester, glutathione isopropyl ester, oxazolidone, and combinations thereof.
3 more elements
A method for suppressing the reproduction of feline immunodeficiency virus and/or feline leukemia virus, comprising administering to a cat:
- (i) at least one NFKB induction inhibitor in art amount effective to inhibit nuclear factor kappa B;
- said at least one NFKB induction inhibitor being selected from the group consisting of anti-inflammatory steroids and nonglucocorticoid lazaroids;
- (ii) at least one fat-soluble antioxidant at doses higher than the recommended dally minimum requirement as appropriately adjusted according to the body weight of the cat;
- (iii) at least one water-soluble antioxidant at doses higher than the recommended dally minimum requirement as appropriately adjusted according to the body weight of the cat;
- and
- (iv) at lease one agent in an amount effective to cause blood glutathione levels to increase, selected from the group consisting of glutathione, N-acetyl cysteine, 2-oxo-4 thiazolidine carboxylic acid, ebselen, oltipraz, L-cysteine, N-acetyl cysteine ethyl ester, N-acetyl cysteine methyl ester, cystamine, cysteamine, penicillamine, 2,3 dimercapto-1-propanol, L-2-oxothiazolidone-4-carboxylate, dimethyl maleate, glutathione ethyl ester, glutathione methyl ester, glutathione isopropyl ester, oxazolidone, and combination thereof.
3 more elements
Dependencies are inferred from the claim text.